Our study assessed the impact of using Control-IQ technology, an automated insulin delivery system, on achievement of a Healthcare Effectiveness Data and Information Set (HEDIS) quality measure ...

SILVER SPRING, Md., Dec. 13, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today authorized marketing of the Tandem Diabetes Care Control-IQ Technology, an interoperable automated ...

Officials in America have approved a system, called Control-IQ, for closed-loop insulin delivery for people with type 1 diabetes. The Control-IQ technology by Tandem Diabetes Care can be used with ...

Tandem Diabetes Care, Inc. TNDM recently commercially launched Control-IQ+ technology - the latest generation of its advanced hybrid closed-loop algorithm in the United States. Control-IQ+ is ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of its new Tandem ...

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – "These new features allow for even greater levels of ...

A new artificial pancreas system, called Control-IQ, has helped people with type 1 diabetes to spend more time in their target glucose range, according to a newly published study. An artificial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Children aged 5 years and younger using automated ...

The t:slim X2 insulin pump (Tandem Diabetes Care) is for continuous subcutaneous insulin delivery to manage blood glucose levels in people with type 1 diabetes. The device is up to 38% smaller than ...

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...